Aptagen, LLC
2F11-14 (ID# 7935)
RNA
Ebola virus inhibitory domain (eVP35 IID) (EBOV) (eVP35)
Protein
7.1 nM (reported value)
10mM HEPES (pH 7.0), 150mM NaCl, 2mM TCEP (tris(2-carboxyethyl)phosphine), 1mM MgCl2
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
rGprGprGprAprGprAprCprAprAprGprAprApUrAprAprAprCprGprCpUrCprAprAprCprGpUUrCprAprGpUrApUrAprAprCprAprGpUrCprCprGprAprGpUrCpUrAprAprCprAprCprAprCprAprApUrGprGprGprAprCprAprCpUrGprAprApUUrCprGprAprCprAprGprGprAprGprGprCpUrCprAprCprAprAprCprAprGprGprCp
78
25439.76
797500
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Jennifer M. Binning, Tianjiao Wang, Priya Luthra, Reed S. Shabman, Dominika M. Borek, Gai Liu, Wei Xu, Daisy W. Leung, Christopher F. Basler, and Gaya K. Amarasinghe, ƒ??Development of RNA aptamers targeting ebolavirus VP35ƒ? Biochemistry 2013, 52, 8406-8419.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.